Literature DB >> 17052946

The natural history of neurological manganism over 18 years.

C-C Huang1, N-S Chu, C-S Lu, R-S Chen, M Schulzer, D B Calne.   

Abstract

We investigated the clinical features and progression of four patients with chronic manganese intoxication, 18 years after cessation of exposure. Because the results were to be compared with previous observations, we employed the same scoring system. The clinical manifestations were foot dystonia, wide based gait, rigidity, and difficulty in walking backwards. Resting tremor was rarely seen, but tongue tremor was found in 2 patients. The asymmetry initially present in 2 patients persisted 18 years later. Measurements had previously revealed rapid progression in the initial 10 years. We found a plateau over the following decade.

Entities:  

Mesh:

Year:  2006        PMID: 17052946     DOI: 10.1016/j.parkreldis.2006.09.002

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  15 in total

1.  Manganese modulation of MAPK pathways: effects on upstream mitogen activated protein kinase kinases and mitogen activated kinase phosphatase-1 in microglial cells.

Authors:  Patrick L Crittenden; Nikolay M Filipov
Journal:  J Appl Toxicol       Date:  2011-01       Impact factor: 3.446

2.  X-ray fluorescence imaging of the hippocampal formation after manganese exposure.

Authors:  Gregory Robison; Taisiya Zakharova; Sherleen Fu; Wendy Jiang; Rachael Fulper; Raul Barrea; Wei Zheng; Yulia Pushkar
Journal:  Metallomics       Date:  2013-11       Impact factor: 4.526

Review 3.  Acquired hepatocerebral degeneration.

Authors:  Joseph Ferrara; Joseph Jankovic
Journal:  J Neurol       Date:  2009-02-17       Impact factor: 4.849

Review 4.  Manganese and its role in Parkinson's disease: from transport to neuropathology.

Authors:  Michael Aschner; Keith M Erikson; Elena Herrero Hernández; Elena Herrero Hernández; Ronald Tjalkens
Journal:  Neuromolecular Med       Date:  2009       Impact factor: 3.843

Review 5.  Are there common biochemical and molecular mechanisms controlling manganism and parkisonism.

Authors:  Jerome A Roth
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

6.  Acquired hepatocerebral degeneration (AHD): a peculiar neurological impairment in advanced chronic liver disease.

Authors:  A Pigoni; F Iuculano; C Saetti; L Airaghi; L Burdick; S Spreafico; M Curioni; R Lombardi; L Valenti; A L Fracanzani; S Fargion
Journal:  Metab Brain Dis       Date:  2017-09-16       Impact factor: 3.584

7.  Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease.

Authors:  Marialuisa Quadri; Antonio Federico; Tianna Zhao; Guido J Breedveld; Carla Battisti; Cathérine Delnooz; Lies-Anne Severijnen; Lara Di Toro Mammarella; Andrea Mignarri; Lucia Monti; Antioco Sanna; Peng Lu; Francesca Punzo; Giovanni Cossu; Rob Willemsen; Fabrizio Rasi; Ben A Oostra; Bart P van de Warrenburg; Vincenzo Bonifati
Journal:  Am J Hum Genet       Date:  2012-02-16       Impact factor: 11.025

8.  Occupational neurotoxic diseases in taiwan.

Authors:  Chi-Hung Liu; Chu-Yun Huang; Chin-Chang Huang
Journal:  Saf Health Work       Date:  2012-11-30

Review 9.  From manganism to manganese-induced parkinsonism: a conceptual model based on the evolution of exposure.

Authors:  Roberto G Lucchini; Christopher J Martin; Brent C Doney
Journal:  Neuromolecular Med       Date:  2009-12-10       Impact factor: 3.843

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.